Suven Life Sciences Ltd.

BSE: SUVEN530239ISIN INE495B01038

Healthcare
Healthcare Research, Analytics & Technology
BSE 1000

Share price

₹276.15+14.80 (+5.66%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹402.90
52W low: ₹124.35
Off 52W high: -31.46%
1M return: -9.78%
3M return: -15.76%
6M return: +29.19%
1Y return: +40.18%
20D avg volume: 43,236
50 DMA: ₹321.15
200 DMA: ₹249.81

Key ratios Consolidated

Market cap: ₹7,803 Cr
Current price: ₹276.15
52W high / low: ₹402.90 / ₹124.35
Face value: ₹1.00
P/E: -22.14
P/B: —
EPS (TTM): ₹-12.47
Book value / share: —
ROE: —
ROCE: -46.50%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹-8.28 Cr
Interest cover: -1,726.12
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: -164.1 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	3.57	1.52	2.81	0.92	1.87	1.47	1.61	2.57	1.01	2.38	2.45	3.06
	7.52	6.78	2.77	3.78	0.60	1.22	1.63	4.04	4.01	4.28	6.07	5.14
	11.09	8.30	5.58	4.70	2.47	2.69	3.24	6.61	5.01	6.67	8.52	8.20
	138.70	53.89	107.50	82.01	53.98	46.63	42.36	56.25	33.05	34.21	50.28	28.34
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	7.28	5.83	6.27	6.08	5.98	6.07	4.87	5.20	4.69	3.46	5.79	4.45
	0.48	0.16	0.00	0.00	0.00	0.00	0.01	0.02	0.02	0.03	0.04	0.04
	2.16	1.58	1.35	1.32	1.37	1.35	1.53	1.46	1.49	1.51	1.60	1.73
	128.79	46.32	99.89	74.61	46.64	39.22	1.82	1.99	1.94	1.69	1.23	1.62
	-127.61	-45.60	-101.92	-77.31	-51.52	-43.95	-39.12	-49.64	-28.04	-27.54	-41.77	-20.14
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.46
	-127.61	-45.60	-101.92	-77.31	-51.52	-43.94	-39.12	-49.64	-28.04	-27.54	-41.77	-12.68
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00
	-127.61	-45.60	-101.92	-77.31	-51.52	-43.95	-39.12	-49.64	-28.04	-26.54	-41.77	-12.68
	-4.84	-2.02	-4.55	-3.48	-2.36	-2.02	-1.79	-2.27	-1.29	-1.22	-1.92	-0.58
Key metrics
	-124.97	-43.86	-100.57	-75.99	-50.15	-42.59	-37.58	-48.16	-26.53	-26.00	-40.13	-10.91
	-3,500.60%	-2,885.50%	-3,579.00%	-8,259.80%	-2,681.80%	-2,897.30%	-2,334.20%	-1,873.90%	-2,626.70%	-1,092.40%	-1,638.00%	-356.50%
	-3,574.50%	-3,000.00%	-3,627.00%	-8,403.30%	-2,755.10%	-2,989.80%	-2,429.80%	-1,931.50%	-2,776.20%	-1,115.10%	-1,704.90%	-414.40%
	—	-7.70%	—	-27.30%	—	-39.30%	—	—	—	—	—	—
	90.90%	3.40%	74.50%	-64.20%	85.10%	-38.20%	-34.30%	-16.00%	—	—	—	—
	-147.70%	-3.80%	-160.50%	-55.70%	-83.70%	-65.60%	6.30%	-291.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	8.82	7.12	6.66	11.69	13.54	11.84
	20.85	13.93	10.90	21.13	8.45	5.32
	29.67	21.05	17.55	32.82	21.99	17.16
	382.10	297.39	178.30	146.36	146.26	139.16
	0.00	0.00	0.00	—	—	—
	0.00	0.00	0.00	—	—	—
	25.46	24.15	20.82	18.99	18.62	21.02
	0.64	0.16	0.05	0.16	0.29	0.53
	6.41	5.61	5.82	6.50	6.54	4.39
	349.61	267.47	151.60	6.28	5.45	6.84
	-352.44	-276.34	-160.75	-113.53	-124.27	-122.00
	0.00	0.00	0.00	7.46	6.00	0.00
	-352.44	-276.34	-160.75	-106.08	-118.27	-122.00
	0.00	0.00	0.00	1.00	0.00	0.00
	-352.44	-276.34	-160.75	-105.08	-118.27	-122.00
	-14.89	-12.13	-7.37	-4.82	-6.63	-9.57
Key metrics
	-345.39	-270.57	-154.88	-99.42	-111.44	-117.08
	-3,915.99%	-3,800.10%	-2,325.50%	-850.50%	-823.00%	-988.90%
	-3,995.92%	-3,881.20%	-2,413.70%	-898.90%	-873.50%	-1,030.40%
	—	-46.50%	-143.90%	—	—	—
	17.29%	6.90%	-43.00%	-13.70%	14.40%	—
	—	-71.90%	-53.00%	11.20%	3.10%	—
	—	-306.87	-191.38	—	—	—
	—	1.09	0.96	—	—	—
	—	0.00	0.00	—	—	—
	—	-8.28	-15.03	—	—	—
	—	-164.1	-200.0	—	—	—
Balance sheet
	—	624.21	135.18	—	—	—
	—	546.71	75.47	—	—	—
	—	8.28	15.03	—	—	—
	—	1.51	1.34	—	—	—
	—	0.10	0.24	—	—	—
	—	21.34	12.63	—	—	—
	—	55.70	59.47	—	—	—
	—	4.81	5.23	—	—	—
	—	30.90	23.49	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	591.40	109.99	—	—	—
Cash flow
	—	-301.79	-154.10	—	—	—
	—	-462.11	154.95	—	—	—
	—	757.15	-0.76	—	—	—
	—	5.08	37.28	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	3.57	1.52	2.81	0.92	1.87	1.47	1.61	2.57	1.01	2.38	2.45	3.06
	7.52	6.78	2.77	3.78	0.59	1.19	1.57	4.04	3.93	4.28	6.07	5.14
	11.09	8.30	5.58	4.70	2.46	2.66	3.18	6.61	4.94	6.67	8.52	8.20
	27.21	19.47	19.05	20.14	17.23	17.73	16.45	17.68	12.60	10.79	13.29	12.90
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	7.28	5.83	6.27	6.08	5.98	6.07	4.87	5.20	4.69	3.46	4.32	4.21
	0.48	0.16	0.00	0.00	0.00	0.00	0.01	0.02	0.02	0.03	0.04	0.04
	2.16	1.58	1.35	1.32	1.37	1.35	1.53	1.46	1.49	1.51	1.60	1.73
	17.30	11.90	11.43	12.75	9.89	10.32	1.78	1.92	1.81	1.61	1.14	1.48
	-16.12	-11.17	-13.47	-15.45	-14.78	-15.07	-13.27	-11.07	-7.67	-4.13	-4.77	-4.70
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	7.46
	-16.12	-11.17	-13.47	-15.45	-14.78	-15.07	-13.27	-11.07	-7.67	-4.13	-4.77	2.75
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	1.00	—	—
	-16.12	-11.17	-13.47	-15.45	-14.78	-15.07	-13.27	-11.07	-7.67	-3.12	-4.77	2.75
	-0.61	-0.50	-0.60	-0.70	-0.68	-0.69	-0.61	-0.51	-0.35	-0.14	-0.22	0.13
Key metrics
	-13.48	-9.43	-12.12	-14.13	-13.41	-13.72	-11.73	-9.59	-6.16	-2.59	-3.13	4.52
	-377.60%	-620.40%	-431.30%	-1,535.90%	-717.10%	-933.30%	-728.60%	-373.20%	-609.90%	-108.80%	-127.80%	147.70%
	-451.50%	-734.90%	-479.40%	-1,679.30%	-790.40%	-1,025.20%	-824.20%	-430.70%	-759.40%	-131.10%	-194.70%	89.90%
	—	-0.70%	—	-1.40%	—	-1.90%	—	—	—	—	—	—
	90.90%	3.40%	74.50%	-64.20%	85.10%	-38.20%	-34.30%	-16.00%	—	—	—	—
	-9.10%	25.90%	-1.50%	-39.60%	-92.70%	-383.00%	-178.20%	-502.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	8.82	7.12	6.66	11.69	13.54	11.84
	20.85	13.91	10.73	21.13	8.45	5.32
	29.67	21.03	17.38	32.82	21.99	17.16
	85.87	75.89	64.46	49.29	48.12	53.41
	0.00	0.00	0.00	—	—	—
	0.00	0.00	0.00	—	—	—
	25.46	24.15	20.82	16.53	15.77	17.46
	0.64	0.16	0.05	0.16	0.29	0.53
	6.41	5.61	5.82	6.50	6.54	4.39
	53.38	45.97	37.77	5.71	5.01	6.49
	-56.21	-54.86	-47.08	-16.47	-26.13	-36.25
	0.00	0.00	0.00	7.46	6.00	—
	-56.21	-54.86	-47.08	-9.01	-20.13	-36.25
	0.00	0.00	0.00	1.00	—	—
	-56.21	-54.86	-47.08	-8.01	-20.13	-36.25
	-2.41	-2.41	-2.16	-0.37	-1.13	-2.84
Key metrics
	-49.16	-49.09	-41.21	-2.35	-13.30	-31.33
	-557.37%	-689.50%	-618.80%	-20.10%	-98.20%	-264.60%
	-637.30%	-770.50%	-706.90%	-68.50%	-148.70%	-306.20%
	—	-3.60%	-5.90%	—	—	—
	17.29%	6.90%	-43.00%	-13.70%	14.40%	—
	—	-16.50%	-487.80%	60.20%	44.50%	—
	—	-74.68	-84.67	—	—	—
	—	1.27	1.01	—	—	—
	—	0.00	0.00	—	—	—
	—	-2.28	-0.46	—	—	—
	—	82.5	-200.0	—	—	—
Balance sheet
	—	1,531	808.89	—	—	—
	—	540.71	57.71	—	—	—
	—	2.28	0.46	—	—	—
	—	1.51	1.34	—	—	—
	—	0.10	0.24	—	—	—
	—	21.34	12.63	—	—	—
	—	55.70	59.47	—	—	—
	—	0.00	5.23	—	—	—
	—	3.75	7.67	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	1,503	799.51	—	—	—
Cash flow
	—	-69.60	-47.39	—	—	—
	—	-685.74	44.21	—	—	—
	—	757.15	-0.76	—	—	—
	—	5.08	37.28	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: -19.29%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +17.29%
Profit YoY (TTM): -3.73%

Consolidated

Sales CAGR 3Y: -19.29%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +17.29%
Profit YoY (TTM): -91.30%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 65.47%

Quarter	September 2026	June 2026
Promoter %	65.47%	65.47%

Holder	Type	Holding	Previous	Change
JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED (In its Capacity as sole trustee of Jasti Family Trust)	Promoter Group	64.93%	64.93%	0.00%
TEJAS TRIVEDI	Public	1.34%	—	—
KETAN C SHETH	Public	1.21%	—	—
SUDHARANI JASTI	Promoter	0.54%	0.54%	0.00%
SIRISHA JASTI	Promoter Group	0.00%	0.00%	0.00%
KALYANI JASTI	Promoter Group	0.00%	0.00%	0.00%
MADHAVI JASTI	Promoter Group	0.00%	0.00%	0.00%
VENKATESWARLU JASTI	Promoter	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Syngene International Limited	16,841	417.20	90.49	8.40%	-5.99% TTM	-60.25% TTM	-35.44%
Indegene Limited	14,870	617.05	36.17	15.40%	+35.84% TTM	-7.78% TTM	+14.61%
Suven Life Sciences Ltd.	7,803	276.15	-22.14	-46.50%	+17.29% TTM	-91.30% TTM	+40.18%
Vimta Labs Ltd.	2,230	498.80	—	—	+4.90% TTM	+48.48% TTM	-24.58%
NOVELIX PHARMACEUTICALS LIMITED S	194	68.00	53.54	6.70%	+179.89% TTM	+535.09% TTM	+29.52%
Bilcare Ltd.	183	77.69	16.51	9.20%	+11.44% TTM	+125.02% TTM	-25.62%
TAKE LIMITED S	170	11.47	29.00	11.10%	-15.35% TTM	+124.35% TTM	-52.11%
Jeevan Scientific Technology Limited	164	81.70	32.02	4.80%	+66.05% TTM	+222.49% TTM	+30.72%
GlobalSpace Technologies Limited	99	28.84	29.21	5.00%	+37.21% TTM	+398.53% TTM	+63.12%
Adeshwar Meditex Limited S	27	18.80	21.36	6.00%	—	—	+1.62%
Vanta Bioscience Limited	14	20.39	—	1.50%	—	—	-5.86%

Filings & corporate actions

Recent announcements

Suven Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Unaudited financial results ....29 Oct 2026 · Board Meeting / Board Meeting
Special Window for Re-lodgment of transfer requests of Physical shares23 Oct 2026 · Company Update / Newspaper Publication
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 20187 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Please find enclosed the News release3 Sep 2026 · Company Update / Press Release / Media Release
Report of Scrutinizer25 Aug 2026 · AGM/EGM / AGM
Outcome of 37th Annual General Meeting25 Aug 2026 · AGM/EGM / AGM
Monitoring Agency Report for the quarter ended 30th June, 202611 Aug 2026 · Company Update / Monitoring Agency Report
Newspaper publication- un-audited finacial results7 Aug 2026 · Company Update / Newspaper Publication
Un-audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 20266 Aug 2026 · Board Meeting / Outcome of Board Meeting
Un-audited Financial results for the quarter ended 30th June, 20266 Aug 2026 · Result / Financial Results
Newspaper Adv. regarding Notice of 37th Annual General Meeting of the Company and E-voting information31 Jul 2026 · Company Update / Newspaper Publication
Suven Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve Un-Audited Financial Results ....30 Jul 2026 · Board Meeting / Board Meeting
Letter to Shareholders regarding Annual Report FY 2025-2630 Jul 2026 · Company Update / General
Business Responsibility and Sustainability Report (BRSR) for FY 2025-2630 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Notice of the 37th Annual General Meeting (AGM) of the Company30 Jul 2026 · AGM/EGM / AGM
Annual Report 2025-26 and Notice of 37th Annual General Meeting (AGM) of the Company30 Jul 2026 · Others / Reg. 34 (1) Annual Report
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & PACs20 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Special window for Re-Lodgment of transfer requests of Physical shares14 Jul 2026 · Company Update / Newspaper Publication
Interaction with Investors and Analysts14 Jul 2026 · Company Update / Analyst / Investor Meet
Please find enclosed News Release of our company10 Jul 2026 · Company Update / Press Release / Media Release
Certificate under Reg 74 (5) of SEBI (DP) Regulations, 20188 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Revised outcome of the meeting of Board of Directors - Incorporation of Wholly owned Subsidiary (WOS) in Singapore8 Jul 2026 · Company Update / General
Incorporation of Wholly owned Subsidiary (WOS) in Singapore8 Jul 2026 · Company Update / General
Re-appointment of Dr. Vajja Sambasiva Rao effective from January 21, 2027 for a second term of 5(five) years8 Jul 2026 · Company Update / Change in Management
Allotment of 18570133 Equity shares of the Company on preferntial basis upon conversion of 18570133 fully paid warrants8 Jul 2026 · Company Update / Allotment of Equity Shares
Outcome of Board Meeting8 Jul 2026 · Others / Outcome without intimation
Closure of Trading Window26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Allotment of 2,71,970 Equity shares upon exercise of vested options under SLSL ESOP 2020 Scheme22 Jun 2026 · Company Update / Allotment of ESOP / ESPS
Please find enclosed News release of our company22 Jun 2026 · Company Update / Press Release / Media Release
Please find enclosed News Release of our Company.17 Jun 2026 · Company Update / Press Release / Media Release
Please find enclosed News Release of our company.16 Jun 2026 · Company Update / Press Release / Media Release
Please find enclosed News Release of our company.12 Jun 2026 · Company Update / Press Release / Media Release
Please find attached News Release of our company4 Jun 2026 · Company Update / Press Release / Media Release
Rectification order for Assesment year 2020-2129 May 2026 · Company Update / General
Clarification on Volume Movement Letter19 May 2026 · Company Update / General
The Exchange has sought clarification from Suven Life Sciences Ltd on May 19, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.19 May 2026 · Company Update / Clarification
Newspaper Publication - Financial Results14 May 2026 · Company Update / Newspaper Publication
Monitoring Agency Report for the quarter ended March 31, 202614 May 2026 · Company Update / Monitoring Agency Report
Grant of Stock options13 May 2026 · Company Update / General

Board meetings

5 Nov 2026 Board Meeting - Financial Results
6 Aug 2026 Board Meeting - Financial Results